文献速递临床试验与 GCP流行病学与生物统计

儿童院外心脏骤停肌注肾上腺素PRIME试验研究方案

Evaluating intramuscular epinephrine in pediatric out-of-hospital cardiac arrest (the PRIME trial): study protocol for a multi-centre, stepped-wedge cluster quasi-randomized controlled trial.
PubMed 文献 · Trials · 2026-06-08

PRIME试验为前瞻性多中心阶梯楔形整群准随机对照试验,在急救服务层面随机分组,评估儿童院外心脏骤停中首剂肌注肾上腺素对比标准治疗能否改善ROSC时间。研究同时评估出院存活、存活且神经功能良好及安全性,注册号NCT05166343。

要点

  • 儿童院外心脏骤停中,肌注肾上腺素无需建立血管通路,可能缩短首剂给药时间。
  • PRIME采用阶梯楔形整群设计,以急救服务为单位随机,每站自身对照。
  • 主要结局为ROSC时间,关键中间结局与生存强相关。

核心结论

  • PRIME试验旨在评估儿童院外心脏骤停中首剂肌注肾上腺素对ROSC时间的影响,并观察出院存活、神经功能良好存活及安全性。

研究设计与样本

  • 前瞻性、多中心、实用性、两臂、开放标签、阶梯楔形整群准随机对照试验,以急救服务为随机单位,各站点自身对照。
  • 因纳入多个异质区域,无法进行个体水平随机化;研究聚焦有限效力检验,采用与生存强相关的中间结局即ROSC时间。

关键数值与推荐

  • 主要目标为比较首剂肌注肾上腺素与标准治疗对ROSC时间的影响。
  • 次要评估包括出院存活、出院存活且神经功能良好及儿童院外心脏骤停管理中的安全性。

临床怎么用

  • 若证实有效,肌注肾上腺素可能为急救人员提供无需血管通路的给药途径,并可能影响复苏指南与标准实践。

局限性

  • 研究为区域性试验,聚焦有限效力检验,采用中间结局ROSC时间而非以生存为主要终点。
  • 因区域异质性和整群设计,无法进行个体水平随机化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pediatric out-of-hospital cardiac arrest (POHCA) is a time-sensitive event with a high mortality rate. Epinephrine is a key first-line medication used during cardiac arrest resuscitation to support perfusion and return of spontaneous circulation (ROSC). Guidelines for the management of POHCA recommend paramedics administer epinephrine as soon as possible by intravenous (IV) or intraosseous (IO) injection. However, successfully inserting an IV or IO line can be challenging in high-stress situations, particularly in a poorly perfused, small child. In contrast, intramuscular (IM) epinephrine, which is the standard of care in anaphylaxis management, does not require paramedics to secure vascular access and may lead to a shorter time to first dose. The POHCA Resuscitation: Evaluation of IM Epinephrine (PRIME) trial aims to evaluate the impact of IM epinephrine on POHCA outcomes. The primary objective of the PRIME trial is to determine if an initial dose of IM epinephrine improves time to return of spontaneous circulation (ROSC) compared to standard of care alone. METHODS: The PRIME trial is a prospective, multi-centre, pragmatic, two-arm, open-label, stepped-wedge cluster quasi-randomized controlled trial. We will randomize at the level of the paramedic service, as individual-level randomization is not possible due to the inclusion of multiple, heterogeneous regions. Each site will serve as its own control. This study is a regional trial, with a focus on limited efficacy testing through an intermediate outcome (i.e., time to ROSC) that is strongly associated with survival. We also aim to evaluate the impact of the intervention on survival to hospital discharge, survival to hospital discharge with favourable neurological outcome, and safety in POHCA management. DISCUSSION: The PRIME trial aims to provide insight into the effectiveness and safety of IM epinephrine in POHCA. The data and analyses generated from the trial have the potential to inform resuscitation guidelines and standard of care practices. TRIAL REGISTRATION: ClinicalTrials.gov NCT05166343, Registered on December 8, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Idrees S, Assaf M, Davis M, et al. Evaluating intramuscular epinephrine in pediatric out-of-hospital cardiac arrest (the PRIME trial): study protocol for a multi-centre, stepped-wedge cluster quasi-randomized controlled trial. Trials. 2026. PMID: 42260675. doi:10.1186/s13063-026-09776-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。